Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

A Eden Evins, M.D.

TitleAssociate Professor of Psychiatry
InstitutionMassachusetts General Hospital
DepartmentPsychiatry
AddressMassachusetts General Hospital
Center for Addiction Medicine
60 Staniford Street
Boston MA 02114
Phone617/643-4679
Fax617/643-1998

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014 Jan 8; 311(2):145-54.
    View in: PubMed
  2. Evins AE. Reassessing the safety of varenicline. Am J Psychiatry. 2013 Dec 1; 170(12):1385-7.
    View in: PubMed
  3. David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2013; 6:CD003086.
    View in: PubMed
  4. Evins AE, Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? J Clin Psychiatry. 2013 Apr; 74(4):e08.
    View in: PubMed
  5. Witte J, Bentley K, Evins AE, Clain AJ, Baer L, Pedrelli P, Fava M, Mischoulon D. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol. 2012 Dec; 32(6):787-96.
    View in: PubMed
  6. Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry. 2012 Nov; 73(11):1463-8.
    View in: PubMed
  7. Roh S, Evins AE. Possible role of nicotine for the treatment of mild cognitive impairment. Expert Rev Neurother. 2012 May; 12(5):531-3.
    View in: PubMed
  8. Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011 Oct; 31(5):597-602.
    View in: PubMed
  9. Janes AC, Smoller JW, David SP, Frederick BD, Haddad S, Basu A, Fava M, Evins AE, Kaufman MJ. Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend. 2012 Jan 1; 120(1-3):7-13.
    View in: PubMed
  10. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl). 2012 Jan; 219(1):25-34.
    View in: PubMed
  11. Mashhoon Y, Janes AC, Jensen JE, Prescot AP, Pachas G, Renshaw PF, Fava M, Evins AE, Kaufman MJ. Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15; 35(7):1709-13.
    View in: PubMed
  12. Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Aug; 72(8):1144-51.
    View in: PubMed
  13. Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, Buchanan RW. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry. 2012 Jan; 73(1):95-102.
    View in: PubMed
  14. Evins AE. Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia. Evid Based Ment Health. 2010 Nov; 13(4):120.
    View in: PubMed
  15. Janes AC, Pizzagalli DA, Richardt S, Frederick Bde B, Holmes AJ, Sousa J, Fava M, Evins AE, Kaufman MJ. Neural substrates of attentional bias for smoking-related cues: an FMRI study. Neuropsychopharmacology. 2010 Nov; 35(12):2339-45.
    View in: PubMed
  16. Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry. 2010 Apr 15; 67(8):722-9.
    View in: PubMed
  17. Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, Goff DC. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010 Apr 30; 176(2-3):99-102.
    View in: PubMed
  18. Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry. 2010 Feb; 22(1):33-42.
    View in: PubMed
  19. Janes AC, Frederick Bd, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ. Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence. Exp Clin Psychopharmacol. 2009 Dec; 17(6):365-73.
    View in: PubMed
  20. Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009 Dec; 70(12):1674-80.
    View in: PubMed
  21. Santesso DL, Evins AE, Frank MJ, Schetter EC, Bogdan R, Pizzagalli DA. Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. Hum Brain Mapp. 2009 Jul; 30(7):1963-76.
    View in: PubMed
  22. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. J Psychiatr Pract. 2009 Jul; 15(4):251-61.
    View in: PubMed
  23. Kaufman MJ, Prescot AP, Ongur D, Evins AE, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009 Aug 30; 173(2):143-9.
    View in: PubMed
  24. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009 Apr; 29(2):165-9.
    View in: PubMed
  25. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol. 2009 Apr; 24(3):225-32.
    View in: PubMed
  26. Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol. 2008 Dec; 28(6):660-6.
    View in: PubMed
  27. Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, Rigotti NA, Evins AE. Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry. 2008 Nov; 69(11):1743-50.
    View in: PubMed
  28. Makris N, Gasic GP, Kennedy DN, Hodge SM, Kaiser JR, Lee MJ, Kim BW, Blood AJ, Evins AE, Seidman LJ, Iosifescu DV, Lee S, Baxter C, Perlis RH, Smoller JW, Fava M, Breiter HC. Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse? Neuron. 2008 Oct 9; 60(1):174-88.
    View in: PubMed
  29. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008 Dec; 106(2-3):320-7.
    View in: PubMed
  30. Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl). 2009 Jan; 202(1-3):411-7.
    View in: PubMed
  31. Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl). 2008 Jul; 199(1):89-98.
    View in: PubMed
  32. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008 Jun; 69(6):1016.
    View in: PubMed
  33. Fan X, Henderson DC, Nguyen DD, Cather C, Freudenreich O, Evins AE, Borba CP, Goff DC. Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Res. 2008 May 30; 159(1-2):140-6.
    View in: PubMed
  34. Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res. 2008 Jul; 102(1-3):88-95.
    View in: PubMed
  35. Loebl T, Angarita GA, Pachas GN, Huang KL, Lee SH, Nino J, Logvinenko T, Culhane MA, Evins AE. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry. 2008 Mar; 69(3):480-6.
    View in: PubMed
  36. Gelenberg AJ, de Leon J, Evins AE, Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders. Prim Care Companion J Clin Psychiatry. 2008; 10(1):52-8.
    View in: PubMed
  37. Barr RS, Pizzagalli DA, Culhane MA, Goff DC, Evins AE. A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry. 2008 Jun 1; 63(11):1061-5.
    View in: PubMed
  38. Pizzagalli DA, Evins AE, Schetter EC, Frank MJ, Pajtas PE, Santesso DL, Culhane M. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl). 2008 Feb; 196(2):221-32.
    View in: PubMed
  39. Gelenberg AJ, de Leon J, Evins AE, Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders. J Clin Psychiatry. 2007 Sep; 68(9):1404-10.
    View in: PubMed
  40. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007 Aug; 27(4):380-6.
    View in: PubMed
  41. Fan X, Henderson DC, Chiang E, Briggs LB, Freudenreich O, Evins AE, Cather C, Goff DC. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res. 2007 Aug; 94(1-3):119-27.
    View in: PubMed
  42. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC, Evins AE. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008 Feb; 33(3):480-90.
    View in: PubMed
  43. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007 Feb; 115(2):101-5.
    View in: PubMed
  44. David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2006; (4):CD003086.
    View in: PubMed
  45. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006 May; 67(5):789-97.
    View in: PubMed
  46. Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord. 2006 Apr; 8(2):168-74.
    View in: PubMed
  47. Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord. 2006 Feb; 8(1):75-80.
    View in: PubMed
  48. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE, Goff DC. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006 Feb; 113(2):142-7.
    View in: PubMed
  49. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, Goff DC. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2005 Sep; 181(2):358-63.
    View in: PubMed
  50. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005 Sep; 66(9):1116-21.
    View in: PubMed
  51. Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry. 2005 Sep; 66(9):1184-90.
    View in: PubMed
  52. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005 Jun; 25(3):218-25.
    View in: PubMed
  53. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005 May; 162(5):954-62.
    View in: PubMed
  54. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005 Feb; 66(2):183-94; quiz 147, 273-4.
    View in: PubMed
  55. O'Donnell WJ, Kradin RL, Evins AE, Wittram C. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia. N Engl J Med. 2004 Dec 23; 351(26):2741-9.
    View in: PubMed
  56. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr; 179(1):144-50.
    View in: PubMed
  57. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004 Oct; 65(10):1372-6.
    View in: PubMed
  58. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004 Sep; 161(9):1705-8.
    View in: PubMed
  59. Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004 Mar; 65(3):307-11; quiz 452-3.
    View in: PubMed
  60. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003 May-Jun; 72(3):115-27.
    View in: PubMed
  61. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry. 2003; 64 Suppl 8:9-14.
    View in: PubMed
  62. Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002 Jul 1; 56(1-2):19-23.
    View in: PubMed
  63. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry. 2002 Mar 15; 51(6):493-7.
    View in: PubMed
  64. Goff DC, Freudenreich O, Evins AE. Augmentation strategies in the treatment of schizophrenia. CNS Spectr. 2001 Nov; 6(11):904, 907-11.
    View in: PubMed
  65. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001 Nov; 3(4):397-403.
    View in: PubMed
  66. Frankle W, Shera D, Berger-Hershkowitz H, Evins A, Connolly C, Goff D, Henderson D. Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. Am J Psychiatry. 2001 Feb; 158(2):270-4.
    View in: PubMed
  67. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000 May; 157(5):826-8.
    View in: PubMed
  68. Evins AE, Tisdale T. Bupropion and smoking cessation. Am J Psychiatry. 1999 May; 156(5):798-9.
    View in: PubMed
  69. Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999 Feb 15; 45(4):512-4.
    View in: PubMed
  70. Goff DC, Evins AE. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry. 1998 Jul-Aug; 6(2):59-77.
    View in: PubMed
  71. Evins AE, Amico ET, Shih V, Goff DC. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm. 1997; 104(6-7):761-6.
    View in: PubMed
  72. Goldring SR, Flannery MS, Petrison KK, Evins AE, Jasty MJ. Evaluation of connective tissue cell responses to orthopaedic implant materials. Connect Tissue Res. 1990; 24(1):77-81.
    View in: PubMed
  73. Milam MG, Evins AE, Sahn SA. Immediate chest roentgenography following fiberoptic bronchoscopy. Chest. 1989 Sep; 96(3):477-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Evins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_